Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Updated Treatment Algorithm of Pulmonary Arterial Hypertension

(2013) Nazzareno Galiè et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

(2013) Hossein-Ardeschir Ghofrani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Riociguat for the Treatment of Pulmonary Arterial Hypertension

(2013) Hossein-Ardeschir Ghofrani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polymorphism of human cytochrome P450 enzymes and its clinical impact

(2009) Shu-Feng Zhou et al.   DRUG METABOLISM REVIEWS

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure

(2009) Veselin Mitrovic et al.   BMC Pharmacology & Toxicology

Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension

(2008) R. T. Schermuly et al.   EUROPEAN RESPIRATORY JOURNAL

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers

(2008) Reiner Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY